

<b>Appendix 3: Characteristics of studies included in the meta-analysis (part 1 of 3)</b>													
Study	Year	Adequate randomization – method described and appropriate	Concealment of allocation	Unit of allocation	Baseline characteristics similar	Groups equally provided with care	Blinding	Calculation of statistical power	Withdrawals and dropouts described	Length of follow-up, mo	intention to treat	Study funding described	Industry sponsored
<b>Insulin v. OAHA</b>													
Groop <sup>1</sup>	1989	Y	N	Y	Y	Y	N	N	N	6	N	N	ND
Klein <sup>2</sup>	1991	Y	N	N	Y	Y	N	N	Y	12	N	N	ND
Yki-Järvinen <sup>3</sup>	1992	Y	Y	Y	Y	Y	N	N	Y	3	N	Y	Y
Rodier <sup>4</sup>	1995	N	N	N	Y	Y	N	N	N	6	N	N	ND
Birkeland <sup>5</sup>	1996	N	N	N	Y	Y	N	N	Y	42	Y	Y	Y
Schwartz <sup>6</sup>	2003	N	N	N	Y	Y	N	Y	Y	6	Y	Y	Y
Hendra <sup>7</sup>	2004	Y	Y	Y	Y	Y	N	N	N	6	N	Y	Y
Ovalle <sup>8</sup>	2004	N	N	N	Y	Y	N	N	N	6	N	Y	Y
Raz <sup>9</sup>	2005	N	N	N	Y	Y	N	Y	Y	4	Y	Y	Y
Ko <sup>10</sup>	2006	N	N	N	N	Y	N	Y	Y	12	Y	N	ND
Ushakova <sup>11</sup>	2007	Y	Y	Y	Y	Y	N	Y	Y	4	Y	Y	Y
Alvarsson <sup>12</sup>	2008	N	N	N	Y	Y	N	N	Y	48	N	Y	Y
Harris <sup>13</sup>	2008	Y	Y	Y	Y	Y	N	N	Y	6	Y	Y	Y
Papa <sup>14</sup>	2008	Y	Y	N	N	Y	N	N	N	6	N	N	ND
<b>Basal v. premixed</b>													
Yki-Järvinen <sup>3</sup>	1992	Y	Y	Y	Y	Y	N	N	Y	3	N	Y	Y
Olsson <sup>15</sup>	2002	N	N	N	N	Y	N	N	N	6	N	N	ND
Kilo <sup>16</sup>	2003	N	N	N	Y	Y	N	N	Y	3	N	Y	Y
Stehouwer <sup>17</sup>	2003	N	N	N	Y	Y	N	N	N	9	N	Y	Y
Goudswaard <sup>18</sup>	2004	N	N	N	N	Y	N	Y	N	12	Y	N	ND
Janka <sup>19</sup>	2005	Y	Y	Y	Y	Y	N	Y	Y	6	Y	Y	Y
Raskin <sup>20</sup>	2005	Y	N	N	Y	Y	N	N	Y	7	Y	Y	Y
Kann <sup>21</sup>	2006	Y	Y	Y	Y	Y	N	Y	Y	7	Y	Y	Y
Kazda <sup>22</sup>	2006	N	N	N	Y	Y	N	Y	Y	6	Y	Y	Y
Davies <sup>23</sup>	2007	Y	N	N	Y	Y	N	Y	Y	4	N	Y	Y
Buse <sup>24</sup>	2009	Y	Y	Y	Y	Y	N	Y	Y	6	Y	Y	Y
Holman <sup>25</sup>	2009	N	N	N	Y	Y	N	N	Y	36	Y	Y	Y
Milicevic <sup>26</sup>	2009	Y	N	Y	Y	Y	N	Y	Y	6	N	Y	Y
Strojek <sup>27</sup>	2009	Y	Y	Y	Y	Y	N	Y	Y	6	Y	Y	Y
Wolffenbuttel <sup>28</sup>	2009	N	N	N	Y	Y	N	N	Y	30	Y	Y	Y

<b>Appendix 3: Characteristics of studies included in the meta-analysis (part 2 of 3)</b>													
Study	Year	Adequate randomization – method described and appropriate	Concealment of allocation	Unit of allocation	Baseline characteristics similar	Groups equally provided with care	Blinding	Calculation of statistical power	Withdrawals and dropouts described	Length of follow-up, mo	intention to treat	Study funding described	Industry sponsored
<b>Basal v. basal-bolus</b>													
Paterson <sup>29</sup>	1991	N	N	N	N	Y	N	N	N	4	N	Y	Y
Yki-Järvinen <sup>3</sup>	1992	Y	Y	Y	Y	Y	N	N	Y	3	N	Y	Y
Landstedt-Hallin <sup>30</sup>	1995	N	N	N	Y	Y	N	N	Y	4	N	Y	Y
Bastyr <sup>31</sup>	1999	Y	N	N	Y	Y	N	N	Y	2	Y	Y	Y
Hendra <sup>7</sup>	2004	Y	Y	Y	Y	Y	N	N	N	6	N	Y	Y
Kazda <sup>22</sup>	2006	N	N	N	Y	Y	N	Y	Y	6	Y	Y	Y
Bretzel <sup>32</sup>	2008	Y	Y	Y	Y	Y	N	Y	Y	10	Y	Y	Y
Holman <sup>25</sup>	2009	N	N	N	Y	Y	N	N	Y	36	Y	Y	Y
<b>Premixed v. basal-bolus</b>													
Yki-Järvinen <sup>3</sup>	1992	Y	Y	Y	Y	Y	N	N	Y	3	N	Y	Y
Abrahamian <sup>33</sup>	2005	N	N	N	Y	Y	N	Y	Y	6	Y	Y	Y
Holman <sup>25</sup>	2009	N	N	N	Y	Y	N	N	Y	36	Y	Y	Y
<b>Intermediate- v. long-acting</b>													
Taylor <sup>34</sup>	2000	N	N	N	Y	Y	N	Y	Y	12	N	Y	Y
Yki-Järvinen <sup>35</sup>	2000	Y	N	N	Y	Y	N	N	N	12	Y	Y	Y
Massi Benedetti <sup>36</sup>	2003	Y	Y	Y	Y	Y	N	Y	Y	12	Y	N	ND
Riddle <sup>37</sup>	2003	Y	Y	Y	Y	Y	N	Y	Y	6	Y	Y	Y
Hermansen <sup>38</sup>	2006	N	N	N	Y	Y	N	Y	Y	6	Y	N	ND
Philis-Tsimikas <sup>39</sup>	2006	Y	Y	Y	Y	Y	N	Y	Y	5	Y	Y	Y
Esposito <sup>40</sup>	2008	Y	Y	Y	Y	Y	N	Y	Y	9	N	Y	N
<b>AM v. HS basal</b>													
Yki-Järvinen <sup>3</sup>	1992	Y	Y	Y	Y	Y	N	N	Y	3	N	Y	Y
Wolffenbuttel <sup>41</sup>	1996	N	N	N	Y	Y	N	N	N	6	Y	Y	N
Zargar <sup>42</sup>	2002	N	N	N	Y	Y	N	N	N	3	N	N	ND
Philis-Tsimikas <sup>39</sup>	2006	Y	Y	Y	Y	Y	N	Y	Y	5	Y	Y	Y
<b>Insulin v. insulin + OAHA</b>													
Lotz <sup>43</sup>	1988	Y	N	N	N	Y	N	N	N	24	Y	N	ND
Wolffenbuttel <sup>44</sup>	1991	Y	N	N	N	Y	N	N	N	6	N	Y	Y
Riddle <sup>45</sup>	1992	Y	N	N	Y	Y	Y	N	N	4	N	N	ND

<b>Appendix 3: Characteristics of studies included in the meta-analysis (part 3 of 3)</b>													
Study	Year	Adequate randomization – method described and appropriate	Concealment of allocation	Unit of allocation	Baseline characteristics similar	Groups equally provided with care	Blinding	Calculation of statistical power	Withdrawals and dropouts described	Length of follow-up, mo	intention to treat	Study funding described	Industry sponsored
<b>Insulin v. insulin + OAHA (continued)</b>													
Yki-Järvinen <sup>3</sup>	1992	Y	Y	Y	Y	Y	N	N	Y	3	N	Y	Y
Chow <sup>46</sup>	1995	Y	N	N	N	Y	N	N	Y	8	N	Y	Y
Shank <sup>47</sup>	1995	Y	Y	Y	Y	Y	Y	N	Y	12	N	Y	Y
Sun <sup>48</sup>	1995	Y	N	N	Y	Y	N	N	N	4	N	Y	Y
Wolffenbuttel <sup>41</sup>	1996	N	N	N	Y	Y	N	N	N	6	Y	Y	N
Fövényi <sup>49</sup>	1997	Y	N	N	Y	Y	N	N	Y	36	N	N	ND
Riddle <sup>50</sup>	1998	Y	N	N	Y	Y	Y	N	Y	6	N	Y	Y
Basty <sup>31</sup>	1999	Y	N	N	Y	Y	N	N	Y	2	Y	Y	Y
Yki•Jarvinen <sup>51</sup>	1999	Y	Y	Y	Y	Y	N	N	Y	12	N	Y	Y
Xu <sup>52</sup>	2001	N	N	N	Y	Y	N	N	N	6	N	N	ND
Olsson <sup>15</sup>	2002	N	N	N	N	Y	N	N	N	6	N	N	ND
Zargar <sup>42</sup>	2002	N	N	N	Y	Y	N	N	N	3	N	N	ND
Atluntas <sup>53</sup>	2003	Y	N	N	Y	Y	N	N	N	6	N	N	ND
Kabadi <sup>54</sup>	2003	Y	Y	Y	Y	Y	Y	N	N	6	N	Y	N
Stehouwer <sup>17</sup>	2003	N	N	N	Y	Y	N	N	N	9	N	Y	Y
Goudswaard <sup>18</sup>	2004	N	N	N	N	Y	N	Y	N	12	Y	N	ND
Douek <sup>55</sup>	2005	Y	Y	Y	Y	Y	Y	Y	Y	12	Y	Y	Y
Janka <sup>19</sup>	2005	Y	Y	Y	Y	Y	N	Y	Y	6	Y	Y	Y
Davies <sup>23</sup>	2007	Y	N	N	Y	Y	N	Y	Y	4	N	Y	Y
Ushakova <sup>11</sup>	2007	Y	Y	Y	Y	Y	N	Y	Y	4	Y	Y	Y
Civera <sup>56</sup>	2008	Y	N	N	Y	Y	N	N	Y	6	N	N	ND
Milicevic <sup>26</sup>	2009	Y	N	Y	Y	Y	N	Y	Y	6	N	Y	Y

Note: ND = not disclosed, OAHA = oral antihyperglycemic agent.

## References

1. Groop L, Widen E, Franssila-Kallunki A, Ekstrand A, Saloranta C, Schalin C, et al. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. *Diabetologia* 1989 Aug;32(8):599-605.
2. Klein W. Sulfonylurea-metformin-combination versus sulfonylurea-insulin-combination in secondary failures of sulfonylurea monotherapy. Results of a prospective randomized study in 50 patients. *Diabete Metab* 1991 May;17(1 Pt 2):235-40.

3. Yki-Jarvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. *N Engl J Med* 1992 Nov 12;327(20):1426-33.
4. Rodier M, Colette C, Gouzes C, Michel F, Crastes de PA, Monnier L. Effects of insulin therapy upon plasma lipid fatty acids and platelet aggregation in NIDDM with secondary failure to oral antidiabetic agents. *Diabetes Res Clin Pract* 1995 Apr;28(1):19-28.
5. Birkeland KI, Rishaug U, Hanssen KF, Vaaler S. NIDDM: a rapid progressive disease. Results from a long-term, randomised, comparative study of insulin or sulphonylurea treatment. *Diabetologia* 1996 Dec;39(12):1629-33.
6. Schwartz S, Sievers R, Strange P, Lyness WH, Hollander P. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. *Diabetes Care* 2003 Aug;26(8):2238-43.
7. Hendra TJ, Taylor CD. A randomised trial of insulin on well-being and carer strain in elderly type 2 diabetic subjects. *J Diabetes Complications* 2004 May;18(3):148-54.
8. Ovalle F, Bell DS. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. *Diabetes Care* 2004 Nov;27(11):2585-9.
9. Raz I, Stranks S, Filipczak R, Joshi P, Lertoft B, Rastam J, et al. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study. *Clin Ther* 2005 Sep;27(9):1432-43.
10. Ko GT, Tsang PC, Wai HP, Kan EC, Chan HC. Rosiglitazone versus bedtime insulin in the treatment of patients with conventional oral antidiabetic drug failure: a 1-year randomized clinical trial. *Adv Ther* 2006 Sep;23(5):799-808.
11. Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, et al. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in Russia. *Clin Ther* 2007 Nov;29(11):2374-84.
12. Alvarsson M, Sundkvist G, Lager I, Berntorp K, Fernqvist-Forbes E, Steen L, et al. Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. *Diabetes Obes Metab* 2008 May;10(5):421-9.
13. Harris S, Yale JF, Dempsey E, Gerstein H. Can family physicians help patients initiate basal insulin therapy successfully?: randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial. *Can Fam Physician* 2008 Apr;54(4):550-8.
14. Papa G, Fedele V, Chiavetta A, Lorenti I, Leotta C, Luca S, et al. Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. *Acta Diabetol* 2008 Mar;45(1):53-9.
15. Olsson PO, Lindstrom T. Combination-therapy with bedtime NPH insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes. *Diabetes Metab* 2002 Sep;28(4 Pt 1):272-7.
16. Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. *J Diabetes Complications* 2003 Nov;17(6):307-13.
17. Stehouwer MH, DeVries JH, Lumeij JA, Ader HJ, Engbers AM, Iperen AA, et al. Combined bedtime insulin--daytime sulphonylurea regimen compared with two different daily insulin regimens in type 2 diabetes: effects on HbA1c and hypoglycaemia rate--a randomised trial. *Diabetes Metab Res Rev* 2003 Mar;19(2):148-52.
18. Goudswaard AN, Stolk RP, Zuithoff P, de Valk HW, Rutten GE. Starting insulin in type 2 diabetes: continue oral hypoglycemic agents? A randomized trial in primary care. *J Fam Pract* 2004 May;53(5):393-9.
19. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. *Diabetes Care* 2005 Feb;28(2):254-9.
20. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. *Diabetes Care* 2005 Feb;28(2):260-5.

21. Kann PH, Wascher T, Zackova V, Moeller J, Medding J, Szocs A, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. *Exp Clin Endocrinol Diabetes* 2006 Oct;114(9):527-32.
22. Kazda C, Hulstrunk H, Helsing K, Langer F, Forst T, Hanefeld M. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. *J Diabetes Complications* 2006 May;20(3):145-52.
23. Davies MJ, Thaware PK, Tringham JR, Howe J, Jarvis J, Johnston V, et al. A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin. *Diabet Med* 2007 Jul;24(7):714-9.
24. Buse JB, Wolffenbittel BH, Herman WH, Shemonsky NK, Jiang HH, Fahrbach JL, et al. DURABILITY of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. *Diabetes Care* 2009 Jun;32(6):1007-13.
25. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. *N Engl J Med* 2009 Oct 29;361(18):1736-47.
26. Milicevic Z, Hancu N, Car N, Ivanyi T, Schwarzenhofer M, Jermendy G. Effect of two starting insulin regimens in patients with type II diabetes not controlled on a combination of oral antihyperglycemic medications. *Exp Clin Endocrinol Diabetes* 2009 May;117(5):223-9.
27. Strojek K, Bebakar WM, Khutsoane DT, Pesic M, Smahelova A, Thomsen HF, et al. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. *Curr Med Res Opin* 2009 Dec;25(12):2887-94.
28. Wolffenbittel BH, Klaff LJ, Bhushan R, Fahrbach JL, Jiang H, Martin S. Initiating insulin therapy in elderly patients with Type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents. *Diabet Med* 2009 Nov;26(11):1147-55.
29. Paterson KR, Wilson M, Kesson CM, Buchan M, Roberts M, Reith SB, et al. Comparison of basal and prandial insulin therapy in patients with secondary failure of sulphonylurea therapy. *Diabet Med* 1991 Jan;8(1):40-3.
30. Landstedt-Hallin L, Adamson U, Arner P, Bolinder J, Lins PE. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. *Diabetes Care* 1995 Aug;18(8):1183-6.
31. Bastyr EJ, III, Johnson ME, Trautmann ME, Anderson JH, Jr., Vignati L. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. *Clin Ther* 1999 Oct;21(10):1703-14.
32. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. *Lancet* 2008 Mar 29;371(9618):1073-84.
33. Abrahamian H, Ludvik B, Scherthaner G, Prager R, Zellenka U, Knudsen L, et al. Improvement of glucose tolerance in type 2 diabetic patients: traditional vs. modern insulin regimens (results from the Austrian Biaspart Study). *Horm Metab Res* 2005 Nov;37(11):684-9.
34. Taylor R, Davies R, Fox C, Sampson M, Weaver JU, Wood L. Appropriate insulin regimes for type 2 diabetes: a multicenter randomized crossover study. *Diabetes Care* 2000 Nov;23(11):1612-8.
35. Yki-Jarvinen H, Dressler A, Ziemer M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. *Diabetes Care* 2000 Aug;23(8):1130-6.
36. Massi BM, Humburg E, Dressler A, Ziemer M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. *Horm Metab Res* 2003 Mar;35(3):189-96.
37. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. *Diabetes Care* 2003 Nov;26(11):3080-6.
38. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. *Diabetes Care* 2006 Jun;29(6):1269-74.

39. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. *Clin Ther* 2006 Oct;28(10):1569-81.
40. Esposito K, Ciotola M, Maiorino MI, Gualdiro R, Schisano B, Ceriello A, et al. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. *Ann Intern Med* 2008 Oct 21;149(8):531-9.
41. Wolffenbittel BH, Sels JP, Rondas-Colbers GJ, Menheere PP, Nieuwenhuijzen Kruseman AC. Comparison of different insulin regimens in elderly patients with NIDDM. *Diabetes Care* 1996 Dec;19(12):1326-32.
42. Zargar AH, Masoodi SR, Laway BA, Wani AI, Bashir MI. Response of regimens of insulin therapy in type 2 diabetes mellitus subjects with secondary failure. *J Assoc Physicians India* 2002 May;50(5):641-6.
43. Lotz N, Bachmann W, Ladik T, et al. Combination therapy with insulin/sulfonylurea in the long-term therapy of type 2 diabetes following “secondary failure”. *Klin Wochenschr* 1988;66:1079-84.
44. Wolffenbittel BH, Rondas-Colbers GJ, Menheere PP, et al. The effects of insulin combined with glibenclamide on glucose and lipid metabolism in patients with type 2 diabetes mellitus. *Ned Tijdschr Geneesk* 1991;135:1080-4.
45. Riddle M, Hart J, Bingham P, et al. Combined therapy for obese type 2 diabetes: supertime mixed insulin with daytime sulfonylurea. *Am J Med Sci* 1992;303:151-6.
46. Chow CC, Tsang LW, Sorensen JP, et al. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. *Diabetes Care* 1995;18:307-14.
47. Shank ML, Del PS, DeFronzo RA. Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM. *Diabetes* 1995;44:165-72.
48. Sun Y, Xiong Y, Yang J. The effectiveness of combined insulin and sulfonylurea in treating non-insulin dependent diabetic patients. *Zhonghua Nei Ke Za Zhi* 1995;34:246-9.
49. Fövényi J, Grosz A, Thaisz E, et al. [Daytime sulfonylurea — bedtime insulin combination therapy in type 2 diabetes.] *Magy Belorv Arch (Hungarian Archive of Internal Medicine)* 1997; 50: 607-13.
50. Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. *Diabetes Care* 1998; 21: 1052-7.
51. Yki-Järvinen H, Ryysy L, Nikkila K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. *Ann Intern Med* 1999;130:389-96.
52. Xu WC, Chen CR, Chen YS. Combination therapy with bedtime insulin and daytime oral hypoglycaemic agents in type 2 diabetic patients. *Hebei Med J* 2001;23-4.
53. Altuntas Y, Ozen B, Ozturk B, et al. Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure. *Diabetes Obes Metab* 2003;5:371-8.
54. Kabadi MU, Kabadi UM. Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus. *Ann Pharmacother* 2003;37:1572-6.
55. Douek IF, Allen SE, Ewings P, et al. Continuing metformin when starting insulin in patients with type 2 diabetes: a double-blind randomized placebo-controlled trial. *Diabet Med* 2005; 22: 634-40.
56. Civera M, Merchante A, Salvador M, et al. Safety and efficacy of repaglinide in combination with metformin and bedtime NPH insulin as an insulin treatment regimen in type 2 diabetes. *Diabetes Res Clin Pract* 2008;79:42-7.